Oral Estrogen (Pills)

Overview

Oral estradiol is the most commonly prescribed form of estrogen for feminising HRT. It is taken as a pill (swallowed), metabolised by the liver, and provides a steady baseline level of estradiol.

Available Forms

Medication	Common Brand Names	Typical Doses
Estradiol valerate (E2V)	Progynova, Estrace	2–8 mg/day
Estradiol hemihydrate	Estrofem, Zumenon	2–8 mg/day
Micronised estradiol	Various generic	2–8 mg/day

How It Works

When swallowed, oral estradiol passes through the digestive system to the liver (first-pass metabolism). The liver converts much of it to estrone (E1), a significantly weaker estrogen. This means:

• Oral estradiol produces a higher E1:E2 ratio compared to other routes
• Higher doses are needed to achieve target E2 levels
• Liver metabolism increases production of clotting factors (VTE risk)

First-pass metabolism

The liver converts approximately 80% of oral estradiol to estrone on first pass. This is why oral estrogen requires higher doses and carries a higher VTE risk compared to transdermal or injectable routes. Estrone is about 4% as potent as estradiol at estrogen receptors.

Dosing Guidelines

Level	Dose
Starting dose	2–4 mg/day
Typical maintenance	4–6 mg/day
High dose	6–8 mg/day
Dosing schedule	Split into 2 doses (morning and evening) for more stable levels

Dosing Tips

• Split your daily dose into two equal portions (e.g., 2 mg morning, 2 mg evening)
• Taking with food may reduce nausea for some people
• Consistency matters — take at roughly the same times each day

Side Effects

Side Effect	Notes
Nausea	Common in first few weeks; usually resolves
Headaches	Can occur with dose changes
Mood changes	Possible mood swings in early weeks
VTE risk	Increased risk of blood clots (see below)
Elevated triglycerides	Oral route raises triglycerides more than transdermal
Gallbladder disease	Increased risk; estrogen promotes gallstone formation

VTE (Blood Clot) Risk

Oral estrogen increases the risk of venous thromboembolism (VTE) — blood clots in the legs (DVT) or lungs (PE). This is due to first-pass liver metabolism increasing clotting factors, particularly Factor IX and XI, and increasing APC resistance.

Risk factors that amplify VTE risk:

• Age over 40–45
• Smoking
• Obesity (BMI > 30)
• Personal or family history of blood clots
• Inherited clotting disorders (Factor V Leiden, etc.)
• Prolonged immobility

If you have any of these risk factors, strongly consider transdermal or injectable estradiol instead.

Monitoring

Test	Frequency	Notes
E2 (estradiol)	Every 3 months until stable	Draw blood at trough (just before next dose)
T (testosterone)	Every 3 months	Target < 50 ng/dL
Lipid panel	Annually	Oral E2 can raise triglycerides
Liver function	Annually	ALT, AST
Blood pressure	Every visit	Estrogen can raise BP in some individuals

Pros vs Cons

Pros	Cons
Widely available prescribed	High E1:E2 ratio (low potency)
Easy to dose and adjust	High VTE risk
Familiar to doctors	Liver metabolism affects clotting
No needles	Daily dosing (can miss doses)
Inexpensive	Can raise triglycerides
Good initial option	Higher doses needed vs other routes

Who Should Avoid Oral Estrogen

• People over 40 (especially over 45)
• Smokers
• Anyone with personal/family history of blood clots
• Anyone with known clotting disorder
• People with high triglycerides or liver disease
• People with migraine with aura (estrogen can worsen)

References

1. Connelly PJ, et al. (2021). Managing the risk of venous thromboembolism in transgender adults undergoing hormone therapy. PMC. https://pmc.ncbi.nlm.nih.gov/articles/PMC6628137/

2. Patel N, et al. (2024). Gender-affirming hormone therapy in the transgender patient: influence on thrombotic risk. PMC. https://pmc.ncbi.nlm.nih.gov/articles/PMC11665511/

3. Irwig MS. (2020). Cardiovascular health in transgender people. JCEM. https://academic.oup.com/jcem/article/105/3/e894/5658514